angelala personal page - To The Moon

angelala

No personal profile

22Follow

3Followers

0Topic

0Badge

2021-01-23

$Bit Digital,Inc(BTBT)$k

2021-06-07

ru is unit

Sorry, the original content has been removed

2021-01-27

.......

Sorry, the original content has been removed

2021-01-26

Good

Xintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94

2021-01-23

Wwwwww

2021-02-05

Yyy

Nuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33

2021-01-31

Yyyy

Sorry, the original content has been removed

2021-01-31

Yyy

Sorry, the original content has been removed

2021-01-30

Yyyy

Senior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot

2021-01-27

.....

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3569217644250851","uuid":"3569217644250851","gmtCreate":1606219510032,"gmtModify":1606219510032,"name":"angelala","pinyin":"angelala","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":22,"tweetSize":40,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.17%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":114194503,"gmtCreate":1623055913802,"gmtModify":1704195136827,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"ru is unit","listText":"ru is unit","text":"ru is unit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114194503","repostId":"1182426186","repostType":4,"isVote":1,"tweetType":1,"viewCount":2818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380962894,"gmtCreate":1612505159518,"gmtModify":1704872100089,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyy","listText":"Yyy","text":"Yyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380962894","repostId":"1194873125","repostType":4,"repost":{"id":"1194873125","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1612484798,"share":"https://ttm.financial/m/news/1194873125?lang=en_US&edition=fundamental","pubTime":"2021-02-05 08:26","market":"hk","language":"zh","title":"Nuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33","url":"https://stock-news.laohu8.com/highlight/detail?id=1194873125","media":"老虎资讯综合","summary":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至","content":"<p>February 5th news,<a href=\"https://laohu8.com/S/06606\">NovoHealth-B</a>To announce the details of the prospectus, it is planned to issue 76,598 million shares, of which approximately 90%, or approximately 68,938 million shares, are under international placing and approximately 10%, or approximately 7,66 million shares, are under local public offering, with an over-allotment option of 15%. The offering price ranged from $22.7 to $26.66 per share, raising up to approximately $2.042 billion. Before handling fee, the entrance fee for each board lot of 500 shares is approximately HK$13,464.33. The company will be listed from today (February 5th) to next Wednesday (10th), and it is expected to be listed on February 18th. The joint sponsors of the company are Goldman Sachs and UBS.</p><p><b>The new channel of Tiger Play opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go to new <<<</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health, established in November 2015, is a pioneer in China's colorectal cancer screening market, aiming to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Changweiqing, is the first and only molecular cancer screening test product approved by the NMPA in China. The company focuses on designing, developing and commercializing cancer screening tests, and its two home-based colorectal cancer screening testing products, Changweiqing and Pupu Tube, collaboratively deal with target populations with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of financial position,</b>During FY2018-2019, the Company recorded total revenue of HK$18.816 million and HK$58.275 million respectively, representing a year-on-year increase of 209.7%, and net losses of HK$224.9 million and HK$106.5 million respectively for the same period. For the first nine months ended 30 September 2019 and 2020, total revenue was HK$35.44 million and HK$35.309 million, respectively, and net loss was HK$62.508 million and HK$530 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of industry,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, representing a CAGR of 3.2%. According to Frost & Sullivan, the cost of treating colorectal cancer imposes a heavy economic burden on the healthcare system in China, with the overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few types of cancer for which regular screening is recommended in the medium-risk population without signs or symptoms of cancer due to its high incidence, high mortality, long tumor development cycle, and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available at the Offer Price, totaling approximately US$124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Clear Pool Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the Company intends to</b></p><p><ul><li>Approximately 40% of which was used to finance the commercialization and further development of the product \"Changweiqing\";</li><li>Approximately 30% is used to fund ongoing and planned early-stage pipeline product research and development; Approximately 15% will be used for potential acquisitions or external introduction of product candidates in the cancer screening field;</li><li>Approximately 5% was used to fund the ongoing sales and marketing of the product \"Pupu Tube\";</li><li>and approximately 10% for general working capital.</li></ul></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-05 08:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 5th news,<a href=\"https://laohu8.com/S/06606\">NovoHealth-B</a>To announce the details of the prospectus, it is planned to issue 76,598 million shares, of which approximately 90%, or approximately 68,938 million shares, are under international placing and approximately 10%, or approximately 7,66 million shares, are under local public offering, with an over-allotment option of 15%. The offering price ranged from $22.7 to $26.66 per share, raising up to approximately $2.042 billion. Before handling fee, the entrance fee for each board lot of 500 shares is approximately HK$13,464.33. The company will be listed from today (February 5th) to next Wednesday (10th), and it is expected to be listed on February 18th. The joint sponsors of the company are Goldman Sachs and UBS.</p><p><b>The new channel of Tiger Play opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go to new <<<</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health, established in November 2015, is a pioneer in China's colorectal cancer screening market, aiming to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Changweiqing, is the first and only molecular cancer screening test product approved by the NMPA in China. The company focuses on designing, developing and commercializing cancer screening tests, and its two home-based colorectal cancer screening testing products, Changweiqing and Pupu Tube, collaboratively deal with target populations with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of financial position,</b>During FY2018-2019, the Company recorded total revenue of HK$18.816 million and HK$58.275 million respectively, representing a year-on-year increase of 209.7%, and net losses of HK$224.9 million and HK$106.5 million respectively for the same period. For the first nine months ended 30 September 2019 and 2020, total revenue was HK$35.44 million and HK$35.309 million, respectively, and net loss was HK$62.508 million and HK$530 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of industry,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, representing a CAGR of 3.2%. According to Frost & Sullivan, the cost of treating colorectal cancer imposes a heavy economic burden on the healthcare system in China, with the overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few types of cancer for which regular screening is recommended in the medium-risk population without signs or symptoms of cancer due to its high incidence, high mortality, long tumor development cycle, and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available at the Offer Price, totaling approximately US$124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Clear Pool Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the Company intends to</b></p><p><ul><li>Approximately 40% of which was used to finance the commercialization and further development of the product \"Changweiqing\";</li><li>Approximately 30% is used to fund ongoing and planned early-stage pipeline product research and development; Approximately 15% will be used for potential acquisitions or external introduction of product candidates in the cancer screening field;</li><li>Approximately 5% was used to fund the ongoing sales and marketing of the product \"Pupu Tube\";</li><li>and approximately 10% for general working capital.</li></ul></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194873125","content_text":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至26.66元，集资最多约20.42亿元。未计手续费，每手500股入场费约13,464.33港元。该公司将于今日（2月5日）起至下周三(10日)招股，预期2月18日挂牌上市。公司联席保荐人为高盛、瑞银。老虎打新通道今天中午11:30开通！去打新<<<据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约1.24亿美元，包括：Invesco Advisers, Inc、Lake Bleu Prime Healthcare Master Fund Limited、清池资本、GIC 、南方基金等。筹资用途方面，公司拟将当中约40%用于为产品「常卫清」的商业化及进一步开发提供资金；约30%用于为正在进行及计划进行的早期阶段管线产品研发提供资金；约15%将用于潜在收购或外部引进癌症筛查领域的候选产品；约5%用于为产品「噗噗管」的持续销售及营销提供资金；以及约10%为一般营运资金。","news_type":1,"symbols_score_info":{"06606":0.9}},"isVote":1,"tweetType":1,"viewCount":3820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312192969,"gmtCreate":1612059853751,"gmtModify":1704867062375,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyyy","listText":"Yyyy","text":"Yyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312192969","repostId":"2107234742","repostType":4,"repost":{"id":"2107234742","kind":"highlight","pubTimestamp":1612055520,"share":"https://ttm.financial/m/news/2107234742?lang=en_US&edition=fundamental","pubTime":"2021-01-31 09:12","market":"hk","language":"zh","title":"Aauto Quicker Final Pricing or 115 Hong Kong Dollars, Capital Crazy Grab optimistic about the market outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2107234742","media":"智通财经网","summary":"【快手最终定价或为115港元 资本疯抢看好后市】持续三天疯狂抢筹显示出市场对“短视频第一股”的普遍期待与认可。最有前景的赛道、3亿多日活跃用户、爆发中的商业化与电商业务，独特的流量分发机制和繁荣的社区生态，都让投资者们对这家公司的未来充满了想象力，成为不容错过的“大牛股”。（智通财经网）","content":"<p>Three days of crazy rush to raise money shows the market's general expectation and recognition of \"the first short video stock\". The most promising track, more than 300 million daily active users, the outbreak of commercialization and e-commerce business, the unique traffic distribution mechanism and the prosperous community ecology all make investors full of imagination about the future of this company, and become a \"big bull stock\" that can't be missed. (Zhitong Finance Network)</p><p>As of 12 noon on January 29th, the application registration for public offering of Aauto Quicker (01024) on the Hong Kong Stock Exchange was officially closed. According to IFR, a media subsidiary of the media, the IPO of Aauto Quicker Hong Kong issued to retail investors received a total of HK$1.28 trillion as of that day.</p><p>Since the announcement of the IPO on January 26th, Aauto Quicker has become the \"hottest\" event in Hong Kong stocks at present. On the 29th, there were market rumors that Aauto Quicker will be issued at the upper limit of the IPO price range of HK$ 115. If this is calculated, the market value of Aauto Quicker's Hong Kong stock market will reach 60.9 billion USD (about 475 billion HK$). If the over-allotment option is calculated, the company's market value can increase by up to 61.7 billion USD (about 481.3 billion HK$)</p><p>Long before Aauto Quicker announced its listing, the market opinion that Aauto Quicker was generally valued within 50 billion US dollars. However, judging from this week's subscription situation, institutional and retail markets are obviously generally optimistic about Aauto Quicker's valuation and subsequent growth space, which triggers the rare \"rush-to-raise action\" of Hong Kong stocks this year.</p><p>On January 26th, only 2 minutes after the opening of Aauto Quicker subscription, the financing amount of HK$ 8 billion released by Futu was exhausted. Many investors even said that the \"collapse\" of individual brokers on the spot showed that the system was busy.</p><p>According to a number of media reports, based on the data of one bank and 14 securities firms, the scale of funds subscribed for Aauto Quicker through institutional margin accounts is about 489.8 billion yuan, which is 465.48 times over-subscribed based on the amount of 1.05 billion yuan raised by public offering. Some analysts said that Aauto Quicker subscription is expected to be overbought by about 634 times.</p><p>Three days of crazy rush to raise money shows the market's general expectation and recognition of \"the first short video stock\". The most promising track, more than 300 million daily active users, the outbreak of commercialization and e-commerce business, the unique traffic distribution mechanism and the prosperous community ecology all make investors full of imagination about the future of this company, and become a \"big bull stock\" that can't be missed.</p><p><b>More than $60 billion or just the starting point</b></p><p>Aauto Quicker has been a low-key development company for many years, and it began to make great strides in 2019. At the moment when the video era is accelerating to replace the graphic era, Aauto Quicker, as the first short video giant to go public, represents a huge opportunity behind the change of communication carrier.</p><p>According to the prospectus of Aauto Quicker, as of September 30th last year, the average daily active users of Aauto Quicker China's applications and applets had reached 305 million, and the average monthly active users had reached 769 million. The latest data shows that the average daily active users of its apps continue to grow.</p><p>The high pricing of HK$ 115 shows the market's true cognition of the prospect of this short video giant: under the premise of steady growth of daily activity, the huge platform ecology began to open the door to commercialization and e-commerce. In just over a year, the GMV of e-commerce exceeded 300 billion, and the advertising revenue of information flow doubled.</p><p><img src=\"https://static.tigerbbs.com/c4cd86fe509256cebb97567c71380f41\" tg-width=\"554\" tg-height=\"462\" referrerpolicy=\"no-referrer\"></p><p>Judging from the current oversubscription ratio, the sale market value of $61.7 billion may only be the starting point, and the market value of Aauto Quicker is expected to continue to rise after the official release. This stems from the judgment of the general trend of video, the current user scale, income structure and growth rate of Aauto Quicker, especially the platform ecology with high stickiness and strong interaction, which is a moat that is difficult for other platforms to imitate.</p><p>In the first three quarters of 2020, a total of 9 billion content sharings occurred on Kuaishou, an increase of 3 billion compared with the first half of 2020. At the same time, more than 1 billion pairs of users who follow each other were added in the third quarter. As of September 30, 2020, the total number of interrelated pairs on Kuaishou platform exceeded 9 billion.</p><p>The above prosperous ecology supports the rapid growth of Aauto Quicker's business and revenue. As of the first 11 months of last year, Aauto Quicker's revenue was 52.5 billion yuan, an increase of 11.8 billion yuan compared with the first three quarters. Among the business income in the first three quarters announced in the prospectus, online marketing services grew rapidly, with revenue reaching 13.3 billion in the first three quarters.</p><p>According to the prospectus, the average online marketing service income of daily active users of Aauto Quicker has increased from 50.9 yuan in the nine months ended September 30, 2020 to 71.4 yuan in the 11 months ended November 30, 2020, which means that the commercialization space is expanding wider and wider, which will greatly increase the large-scale income.</p><p>Aauto Quicker e-commerce is another bright spot. Since its inception in 2018, Aauto Quicker e-commerce has developed rapidly. From the total order volume, it has become the \"fourth pole\" of the e-commerce industry, and has the potential to continue to make breakthroughs. According to the prospectus, as of November 30th last year, the GMV of Aauto Quicker e-commerce reached 332.6 billion yuan, which has exceeded five times the GMV of 2019.</p><p>In addition to online marketing and e-commerce business, Aauto Quicker is gradually increasing its weight and layout in games, online knowledge sharing, local life and other fields. With the support of the underlying technology and platform ecology, these businesses complement each other and are building a prosperous business ecosystem of Aauto Quicker, which in turn supports higher scale and market value.</p>","source":"eastmoney_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aauto Quicker Final Pricing or 115 Hong Kong Dollars, Capital Crazy Grab optimistic about the market outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAauto Quicker Final Pricing or 115 Hong Kong Dollars, Capital Crazy Grab optimistic about the market outlook\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经网</strong><span class=\"h-time small\">2021-01-31 09:12</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Three days of crazy rush to raise money shows the market's general expectation and recognition of \"the first short video stock\". The most promising track, more than 300 million daily active users, the outbreak of commercialization and e-commerce business, the unique traffic distribution mechanism and the prosperous community ecology all make investors full of imagination about the future of this company, and become a \"big bull stock\" that can't be missed. (Zhitong Finance Network)</p><p>As of 12 noon on January 29th, the application registration for public offering of Aauto Quicker (01024) on the Hong Kong Stock Exchange was officially closed. According to IFR, a media subsidiary of the media, the IPO of Aauto Quicker Hong Kong issued to retail investors received a total of HK$1.28 trillion as of that day.</p><p>Since the announcement of the IPO on January 26th, Aauto Quicker has become the \"hottest\" event in Hong Kong stocks at present. On the 29th, there were market rumors that Aauto Quicker will be issued at the upper limit of the IPO price range of HK$ 115. If this is calculated, the market value of Aauto Quicker's Hong Kong stock market will reach 60.9 billion USD (about 475 billion HK$). If the over-allotment option is calculated, the company's market value can increase by up to 61.7 billion USD (about 481.3 billion HK$)</p><p>Long before Aauto Quicker announced its listing, the market opinion that Aauto Quicker was generally valued within 50 billion US dollars. However, judging from this week's subscription situation, institutional and retail markets are obviously generally optimistic about Aauto Quicker's valuation and subsequent growth space, which triggers the rare \"rush-to-raise action\" of Hong Kong stocks this year.</p><p>On January 26th, only 2 minutes after the opening of Aauto Quicker subscription, the financing amount of HK$ 8 billion released by Futu was exhausted. Many investors even said that the \"collapse\" of individual brokers on the spot showed that the system was busy.</p><p>According to a number of media reports, based on the data of one bank and 14 securities firms, the scale of funds subscribed for Aauto Quicker through institutional margin accounts is about 489.8 billion yuan, which is 465.48 times over-subscribed based on the amount of 1.05 billion yuan raised by public offering. Some analysts said that Aauto Quicker subscription is expected to be overbought by about 634 times.</p><p>Three days of crazy rush to raise money shows the market's general expectation and recognition of \"the first short video stock\". The most promising track, more than 300 million daily active users, the outbreak of commercialization and e-commerce business, the unique traffic distribution mechanism and the prosperous community ecology all make investors full of imagination about the future of this company, and become a \"big bull stock\" that can't be missed.</p><p><b>More than $60 billion or just the starting point</b></p><p>Aauto Quicker has been a low-key development company for many years, and it began to make great strides in 2019. At the moment when the video era is accelerating to replace the graphic era, Aauto Quicker, as the first short video giant to go public, represents a huge opportunity behind the change of communication carrier.</p><p>According to the prospectus of Aauto Quicker, as of September 30th last year, the average daily active users of Aauto Quicker China's applications and applets had reached 305 million, and the average monthly active users had reached 769 million. The latest data shows that the average daily active users of its apps continue to grow.</p><p>The high pricing of HK$ 115 shows the market's true cognition of the prospect of this short video giant: under the premise of steady growth of daily activity, the huge platform ecology began to open the door to commercialization and e-commerce. In just over a year, the GMV of e-commerce exceeded 300 billion, and the advertising revenue of information flow doubled.</p><p><img src=\"https://static.tigerbbs.com/c4cd86fe509256cebb97567c71380f41\" tg-width=\"554\" tg-height=\"462\" referrerpolicy=\"no-referrer\"></p><p>Judging from the current oversubscription ratio, the sale market value of $61.7 billion may only be the starting point, and the market value of Aauto Quicker is expected to continue to rise after the official release. This stems from the judgment of the general trend of video, the current user scale, income structure and growth rate of Aauto Quicker, especially the platform ecology with high stickiness and strong interaction, which is a moat that is difficult for other platforms to imitate.</p><p>In the first three quarters of 2020, a total of 9 billion content sharings occurred on Kuaishou, an increase of 3 billion compared with the first half of 2020. At the same time, more than 1 billion pairs of users who follow each other were added in the third quarter. As of September 30, 2020, the total number of interrelated pairs on Kuaishou platform exceeded 9 billion.</p><p>The above prosperous ecology supports the rapid growth of Aauto Quicker's business and revenue. As of the first 11 months of last year, Aauto Quicker's revenue was 52.5 billion yuan, an increase of 11.8 billion yuan compared with the first three quarters. Among the business income in the first three quarters announced in the prospectus, online marketing services grew rapidly, with revenue reaching 13.3 billion in the first three quarters.</p><p>According to the prospectus, the average online marketing service income of daily active users of Aauto Quicker has increased from 50.9 yuan in the nine months ended September 30, 2020 to 71.4 yuan in the 11 months ended November 30, 2020, which means that the commercialization space is expanding wider and wider, which will greatly increase the large-scale income.</p><p>Aauto Quicker e-commerce is another bright spot. Since its inception in 2018, Aauto Quicker e-commerce has developed rapidly. From the total order volume, it has become the \"fourth pole\" of the e-commerce industry, and has the potential to continue to make breakthroughs. According to the prospectus, as of November 30th last year, the GMV of Aauto Quicker e-commerce reached 332.6 billion yuan, which has exceeded five times the GMV of 2019.</p><p>In addition to online marketing and e-commerce business, Aauto Quicker is gradually increasing its weight and layout in games, online knowledge sharing, local life and other fields. With the support of the underlying technology and platform ecology, these businesses complement each other and are building a prosperous business ecosystem of Aauto Quicker, which in turn supports higher scale and market value.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://finance.eastmoney.com/a/202101301796196362_0.html\">智通财经网</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/091937ce04164cadd922956ff20a4952","relate_stocks":{},"source_url":"http://finance.eastmoney.com/a/202101301796196362_0.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2107234742","content_text":"持续三天疯狂抢筹显示出市场对“短视频第一股”的普遍期待与认可。最有前景的赛道、3亿多日活跃用户、爆发中的商业化与电商业务，独特的流量分发机制和繁荣的社区生态，都让投资者们对这家公司的未来充满了想象力，成为不容错过的“大牛股”。（智通财经网）\n截至1月29日中午12点，快手(01024)在香港联交所公开发售的申请登记办理正式截止。据媒体旗下媒体IFR报道，快手香港IPO面向散户发行部分截至当日共获得1.28万亿港元认购。\n自1月26日公布招股以来，快手打新成为当下港股“最热门”事件。29日有市场传闻称，快手将以招股价范围的上限115港元发行。若以此计算，快手登陆港股的发售市值将达到609亿美元(约4750亿港元)，若计算上超额配售权，公司发售市值最多可增值617亿美元(约4813亿港元)\n早在快手公布上市之前，市场观点对快手估值普遍在500亿美金以内。但从本周认购情况看，机构及散户市场显然普遍看好快手估值与后续上涨空间，并以此触发港股今年以来罕见的“抢筹行动”。\n1月26日，在快手认购开场仅仅2分钟，富途率先释放的80亿港元融资额度便消耗殆尽，甚至不少投资者表示，个别券商当场“崩溃”显示系统繁忙。\n多家媒体报道，综合1间银行及14家券商的数据，通过机构保证金账户认购快手的资金规模约4898亿元，以公开发售募资额10.5亿元算，超额认购465.48倍。有分析人士表示，快手认购预计将超购约634倍。\n持续三天疯狂抢筹显示出市场对“短视频第一股”的普遍期待与认可。最有前景的赛道、3亿多日活跃用户、爆发中的商业化与电商业务，独特的流量分发机制和繁荣的社区生态，都让投资者们对这家公司的未来充满了想象力，成为不容错过的“大牛股”。\n　600多亿美元或仅是起点\n快手多年来是一家低调发展的公司，2019年开始大踏步进击。在视频时代加速替代图文时代的当下，快手作为第一家上市的短视频巨头，代表了沟通载体变迁背后的巨大机会。\n快手招股书披露，截至去年9月30日，快手中国应用程序及小程序的平均日活用户已达3.05亿，平均月活跃用户达7.69亿。最新数据显示，其应用程序平均日活用户还在持续增长。\n115港元的高定价，显示出市场对这家短视频巨头前景的真实认知：日活稳定增长的前提下，庞大的平台生态开始向商业化和电商打开大门，仅一年多时间，电商GMV就超过3000亿，信息流广告收入翻倍增长。\n\n仅从眼下超额认购的倍率来看，617亿美元的发售市值可能仅为起点，快手市值有望在正式发行后持续拉高，这源于对视频化大趋势的判断、快手当前的用户规模、收入结构和增长速度，尤其高粘性、强互动的平台生态，是其他平台难以模仿的护城河。\n2020年前三季度，快手上总共发生了90亿次内容分享，相比2020年上半年新增30亿次。同时，第三季度还增加了超10亿对互相关注的用户，截至2020年9月30日，快手平台的互关总对数超过90亿。\n上述繁荣生态支撑了快手业务和收入高速增长。截至去年前11个月，快手营收525亿元人民币，相比前三季度增长118亿。在招股书公布的前三季度业务收入中，线上营销服务增长迅速，前三季度收入达到133亿。\n招股书显示，快手日活跃用户平均线上营销服务收入从2020年9月30日止9个月的50.9元，上涨到了2020年11月30日止11个月的71.4元，意味着商业化空间正在越拓越宽，将大幅增加规模化收入。\n快手电商则是另一个亮点。自2018年起步以来，快手电商迅猛发展，从订单总量看已经成为电商行业“第四极”，并具备继续突破的潜力。招股书显示，截至去年11月30日，快手电商GMV达到3326亿元人民币，已经超过2019年全年GMV的5倍。\n除了线上营销、电商业务外，游戏、在线知识分享、本地生活等领域快手也在逐步加码和布局。在底层技术和平台生态支撑下，这些业务相辅相成，正在打造快手繁荣的商业生态系统，进而支撑起更高规模与市值。","news_type":1,"symbols_score_info":{"90022":0.9}},"isVote":1,"tweetType":1,"viewCount":3136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312196465,"gmtCreate":1612059836257,"gmtModify":1704867062052,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyy","listText":"Yyy","text":"Yyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312196465","repostId":"2107223244","repostType":4,"isVote":1,"tweetType":1,"viewCount":3264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312940444,"gmtCreate":1612002519588,"gmtModify":1704866900239,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyyy","listText":"Yyyy","text":"Yyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312940444","repostId":"2107408692","repostType":4,"repost":{"id":"2107408692","kind":"highlight","pubTimestamp":1611985051,"share":"https://ttm.financial/m/news/2107408692?lang=en_US&edition=fundamental","pubTime":"2021-01-30 13:37","market":"us","language":"zh","title":"Senior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot","url":"https://stock-news.laohu8.com/highlight/detail?id=2107408692","media":"智通财经网","summary":"美联储高官更担心经济降温，而不是市场过热。","content":"<p>Mary Daly, president of the Federal Reserve Bank of San Francisco, said the U.S. central bank should not prematurely withdraw support for the U.S. economy just because someone made a fortune in the stock market.</p><p>She said Friday in an online discussion moderated by the Stanford Business School that she was more worried about the cooling economy than about the overheating of the stock market.</p><p>She said that the U.S. stock market is running quite well, and many rich people have gained more wealth, but she felt that it can't remove the \"bridge\" and harm people's livelihoods, leaving people without jobs, income and wage growth.</p><p>Daly voted on monetary policy this year. Recently, the market frenzy has pushed the share price of GameStop (GME.US) to skyrocket. Some people have accused the central bank's ultra-loose policy of fueling the bubble in the financial market. However, so far, the U.S. policy layer has not shown a tendency to withdraw easing.</p><p>At its meeting this week, the Fed determined to keep interest rates near zero and reiterated that it would continue to provide massive monetary assistance for some time to come. Federal Reserve Chairman Powell was also asked several times about excessive market speculation. He avoided commenting directly on the GameStop incident, only saying that the financial stability has been moderately fragile recently.</p><p>At a press conference on Wednesday, Powell said that the Fed's ultra-loose monetary policy did not fuel the bubble, and these were not the focus of the Fed. He stressed that the current Fed's monetary policy is \"just right\" and the Fed will continue to maintain its ultra-loose policy until the labor market returns to what the monetary authorities consider to be the maximum employment level; While allowing inflation to exceed the previous target of 2% to make up for past gaps.</p><p>More action could also be taken on asset purchases if necessary, and talk of slowing them is premature at this time, he added.</p>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经网</strong><span class=\"h-time small\">2021-01-30 13:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Mary Daly, president of the Federal Reserve Bank of San Francisco, said the U.S. central bank should not prematurely withdraw support for the U.S. economy just because someone made a fortune in the stock market.</p><p>She said Friday in an online discussion moderated by the Stanford Business School that she was more worried about the cooling economy than about the overheating of the stock market.</p><p>She said that the U.S. stock market is running quite well, and many rich people have gained more wealth, but she felt that it can't remove the \"bridge\" and harm people's livelihoods, leaving people without jobs, income and wage growth.</p><p>Daly voted on monetary policy this year. Recently, the market frenzy has pushed the share price of GameStop (GME.US) to skyrocket. Some people have accused the central bank's ultra-loose policy of fueling the bubble in the financial market. However, so far, the U.S. policy layer has not shown a tendency to withdraw easing.</p><p>At its meeting this week, the Fed determined to keep interest rates near zero and reiterated that it would continue to provide massive monetary assistance for some time to come. Federal Reserve Chairman Powell was also asked several times about excessive market speculation. He avoided commenting directly on the GameStop incident, only saying that the financial stability has been moderately fragile recently.</p><p>At a press conference on Wednesday, Powell said that the Fed's ultra-loose monetary policy did not fuel the bubble, and these were not the focus of the Fed. He stressed that the current Fed's monetary policy is \"just right\" and the Fed will continue to maintain its ultra-loose policy until the labor market returns to what the monetary authorities consider to be the maximum employment level; While allowing inflation to exceed the previous target of 2% to make up for past gaps.</p><p>More action could also be taken on asset purchases if necessary, and talk of slowing them is premature at this time, he added.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/404125.html\">智通财经网</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/source/image/57164.png?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","PSQ":"做空纳斯达克100指数ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","TQQQ":"纳指三倍做多ETF","UDOW":"三倍做多道指30ETF-ProShares","UPRO":"三倍做多标普500ETF-ProShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares","QID":"两倍做空纳斯达克指数ETF-ProShares","DJX":"1/100道琼斯","SPY":"标普500ETF","OEX":"标普100","SSO":"2倍做多标普500ETF-ProShares","IVV":"标普500ETF-iShares","DXD":"两倍做空道琼30指数ETF-ProShares","QQQ":"纳指100ETF","SDOW":"三倍做空道指30ETF-ProShares",".DJI":"道琼斯","SDS":"两倍做空标普500 ETF-ProShares","OEF":"标普100指数ETF-iShares","SH":"做空标普500-Proshares",".IXIC":"NASDAQ Composite","DOG":"道指ETF-ProShares做空",".SPX":"S&P 500 Index","SQQQ":"纳指三倍做空ETF"},"source_url":"http://www.zhitongcaijing.com/content/detail/404125.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2107408692","content_text":"旧金山联邦储备银行行长Mary Daly说，美国央行不应仅仅因为有人在股市发了财就过早地撤回对美国经济的支持。她本周五在斯坦福大学商学院主持的线上讨论中表示，更担心经济降温，而不是股市过热。她表示，美国股市运行得相当好，许多有钱人获得了更多的财富，但是她觉得不能因此撤走“桥梁”，损害人们的生计，让民众没有工作、没有收入、没有工资增长。Daly今年就货币政策进行了投票。近日，市场的狂热情绪推动GameStop(GME.US)公司股价暴涨，一些人指责央行的超宽松政策助长了金融市场的泡沫，但迄今为止，美国政策层还没有表现出撤回宽松倾向。美联储在本周的会议上确定将利率维持在接近零的水平，并重申将在未来一段时间内继续提供大规模货币援助。美联储主席鲍威尔也数度被问及市场过度投机的问题，他回避了直接评论GameStop事件，只是表示近期金融稳定性出现了些微（moderate）的脆弱。在周三的新闻发布会上，鲍威尔称，美联储的超宽松货币政策没有助长泡沫，这些也不是美联储关注的重点。他强调，目前美联储的货币政策“刚刚好”，美联储将继续维持超宽松政策，直到劳动力市场恢复到货币当局所认为的最大就业水平；同时允许通胀率超过此前2%的目标，以弥补过去的缺口。他补充道，如有必要，还可以在资产购买方面采取更多行动，关于减缓资产购买的讨论目前还为时过早。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"QQQ":0.9,".DJI":0.9,"PSQ":0.9,"MNQmain":0.9,"IVV":0.9,"TQQQ":0.9,"SPY":0.9,"SSO":0.9,"NQmain":0.9,"SDS":0.9,"DJX":0.9,"UDOW":0.9,"SPXU":0.9,"ESmain":0.9,"UPRO":0.9,"QLD":0.9,"SQQQ":0.9,"OEF":0.9,"OEX":0.9,"DXD":0.9,".IXIC":0.9,"QID":0.9,"DDM":0.9,"DOG":0.9,".SPX":0.9,"SH":0.9,"SDOW":0.9}},"isVote":1,"tweetType":1,"viewCount":4106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313562295,"gmtCreate":1611739764717,"gmtModify":1704862515159,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":".....","listText":".....","text":".....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313562295","repostId":"1179238944","repostType":4,"isVote":1,"tweetType":1,"viewCount":3100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313568316,"gmtCreate":1611739665935,"gmtModify":1704862511442,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Wwwww","listText":"Wwwww","text":"Wwwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313568316","repostId":"2106289442","repostType":2,"isVote":1,"tweetType":1,"viewCount":4306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313561335,"gmtCreate":1611739584827,"gmtModify":1704862510471,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":".......","listText":".......","text":".......","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313561335","repostId":"1150077403","repostType":4,"isVote":1,"tweetType":1,"viewCount":3736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313563530,"gmtCreate":1611739526220,"gmtModify":1704862509336,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"...","listText":"...","text":"...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313563530","repostId":"1117723926","repostType":4,"repost":{"id":"1117723926","kind":"news","pubTimestamp":1611739407,"share":"https://ttm.financial/m/news/1117723926?lang=en_US&edition=fundamental","pubTime":"2021-01-27 17:23","market":"hk","language":"zh","title":"Didi takes a stake in AIWAYS, a new car-making force","url":"https://stock-news.laohu8.com/highlight/detail?id=1117723926","media":"第一财经","summary":"爱驰汽车已经快两年没有从资本市场拿到钱了，如何活下去？将近两年没拿到新融资的新势力爱驰汽车，近日传出来新的股东变更消息。据天眼查显示，滴滴旗下上饶市滴滴科技有限公司（下称“上饶滴滴”）、山西合盛新动能","content":"<p><div>AIWAYS hasn't gotten money from the capital market for almost two years. How can it survive? AIWAYS, a new force that has not received new financing for nearly two years, recently reported the news of a new shareholder change. According to Tianyancha, Didi's Shangrao Didi Technology Co., Ltd. (hereinafter referred to as \"Shangrao Didi\") and Shanxi Hesheng New Kinetic Energy Equity Investment Partnership (hereinafter referred to as Shanxi Hesheng) invested in AIWAYS, and completed the industrial and commercial registration of equity change on January 26th. Among them, Shangrao Didi holds 0.37% and Shanxi Hesheng holds 2.9%. From the shareholding ratio, Shangrao Didi does not hold many shares in AIWAYS. What are the intentions of the two?...</p><p><a href=\"http://yicai.com/news/100930581.html\">Web link</a></div></p>","source":"dyvj","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Didi takes a stake in AIWAYS, a new car-making force</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDidi takes a stake in AIWAYS, a new car-making force\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">第一财经</strong><span class=\"h-time small\">2021-01-27 17:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>AIWAYS hasn't gotten money from the capital market for almost two years. How can it survive? AIWAYS, a new force that has not received new financing for nearly two years, recently reported the news of a new shareholder change. According to Tianyancha, Didi's Shangrao Didi Technology Co., Ltd. (hereinafter referred to as \"Shangrao Didi\") and Shanxi Hesheng New Kinetic Energy Equity Investment Partnership (hereinafter referred to as Shanxi Hesheng) invested in AIWAYS, and completed the industrial and commercial registration of equity change on January 26th. Among them, Shangrao Didi holds 0.37% and Shanxi Hesheng holds 2.9%. From the shareholding ratio, Shangrao Didi does not hold many shares in AIWAYS. What are the intentions of the two?...</p><p><a href=\"http://yicai.com/news/100930581.html\">Web link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://yicai.com/news/100930581.html\">第一财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/64a2d9cebdd7adf6a0f7e99103b0b6af","relate_stocks":{},"source_url":"http://yicai.com/news/100930581.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117723926","content_text":"爱驰汽车已经快两年没有从资本市场拿到钱了，如何活下去？将近两年没拿到新融资的新势力爱驰汽车，近日传出来新的股东变更消息。据天眼查显示，滴滴旗下上饶市滴滴科技有限公司（下称“上饶滴滴”）、山西合盛新动能股权投资合伙企业（下称山西合盛）入股爱驰汽车，已于1月26日完成股权变更工商登记。其中，上饶滴滴持股0.37%，山西合盛持股2.9%。从持股比例上看，上饶滴滴所持爱驰汽车的股份并不多，二者意欲何为？记者尝试咨询爱驰汽车相关负责人，但对方不予置评。成立于2017年的爱驰汽车，总部及技术中心设立在上海，高管团队大多出身传统车企。其中，联合创始人、总裁付强曾在一汽-大众、北京奔驰、沃尔沃工作，曾担任沃尔沃汽车(中国)销售有限公司总裁，前联合创始人兼CEO谷峰曾在上汽集团担任过多年的CFO职务。过去几年，多家造车新势力在资本市场上“跑马圈地”的同时，爱驰汽车虽然也通过3轮融资拿到了超过70亿元的资金，但谷峰此前曾在接受第一财经记者采访时表示，爱驰汽车并不担心融资的问题，他还说“上来拿个100亿元，老股东、管理层的股份都稀释掉了。管理层（股份）稀释得越低，新的投资人就不会进来。”2019年5月，爱驰汽车获得江西省发展升级引导基金旗下的明驰基金10亿战略融资。此后，便没有任何关于融资的消息传出。爱驰汽车首款量产车型爱驰U5在2019年4月开启预订，于当年12月正式上市。但上市后不久，新冠肺炎疫情爆发，影响了爱驰汽车的销量。2020年的成都车展上，付强称“爱驰要活下来，今年需要完成1.3万辆的销量”。随后，爱驰汽车内部开始实行高管“全员带货”、“全员营销”，并一度将其与高管和员工的绩效收入挂钩。此后，爱驰汽车还拿到了部分欧洲的出口订单。但据全国乘联会的数据，2020年爱驰汽车累计销量仅为2600辆，没有完成设定目标。在目前资本市场的资源都向着头部企业倾斜的大背景下，销量低迷的爱驰汽车如何能够获得更多资方的支持？付强去年9月对第一财经记者表示，爱驰汽车的B轮融资即将关闭，在IPO（科创板）之前还将进行一轮融资，通过融资来完善投资人结构。但截至目前，该公司B轮融资尚未有任何的消息传出。“IPO并非最终阶段，它能够解决的只是一个企业活着与死去的问题，而企业走得好不好，能不能走到底，依然是个问题。”付强说。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":4585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":319782582,"gmtCreate":1611623647346,"gmtModify":1704861439547,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319782582","repostId":"1163889952","repostType":4,"repost":{"id":"1163889952","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611616215,"share":"https://ttm.financial/m/news/1163889952?lang=en_US&edition=fundamental","pubTime":"2021-01-26 07:10","market":"hk","language":"zh","title":"Xintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94","url":"https://stock-news.laohu8.com/highlight/detail?id=1163889952","media":"老虎资讯综合","summary":"1月26日，心通医疗-B于2021年1月26日-29日招股，公司拟全球发售约2.056亿股，香港发售股份占10%，国际发售股份占90%，另有15%超额配股权。每股11.1-12.2港元，每手1000股","content":"<p>On January 26,<a href=\"https://laohu8.com/S/02160\">Xintong Medical-B</a>In the IPO from 26 to 29 January 2021, the Company intends to offer approximately 205.6 million shares globally, representing 10% of the Hong Kong Offer Shares, 90% of the International Offer Shares, and a 15% over-allotment option. It is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on 4 February 2021.</p><p><b>The new channel of Tiger Securities is expected to open at 14: 00 noon:</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Create a new entry</b></a></p><p><img src=\"https://static.tigerbbs.com/693c26afc147ec7fa1ebdb4eb1a1ebe8\" tg-width=\"967\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has a lot of 1,000 shares and an admission fee of approximately HK$12,322.94.</p><p>Group B has 450,000 shares, and the funds required for subscription are about HK$5,545,322.73.</p><p><img src=\"https://static.tigerbbs.com/38e952a41dfccdab7697b55b35f4cacf\" tg-width=\"1126\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p>The company is a Chinese medical device company focused on the R&D and commercialization of innovative transcatheter and surgical solutions in the field of heart valve diseases. The company's mission is to continue to innovate and provide patients with heart valve disease with the best inclusive healthcare solutions that can improve their quality of life.</p><p>The company's self-developed first-generation transcatheter aortic valve implantation (TAVI) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. The second-generation TAVI product, VitaFlowTM II, has completed registration clinical trials in China and is undergoing clinical trials in Europe. The company submitted the registration application for VitaFlowTM II to the NMPA in October 2020. The application was accepted by the NMPA in November 2020 and is currently under review. It is currently expected to complete the registration of VitaFlowTM II in China by the end of 2021. Separately, the company plans to apply for the CE marking of VitaFlowTM II by the end of 2021. According to Frost & Sullivan, as of the Latest Practicable Date, VitaFlow™ II was the only TAVI product that was developed in China and has commenced clinical trials in Europe.</p><p>As of the Latest Practicable Date, the Company owned 98 patents in China, including 23 invention patents, 68 utility model patents and 7 industrial designs. As of the same date, there were also 82 pending patent applications in China, including 72 invention patents and 10 utility model patents. To promote the Company's strategy to enter overseas markets, it also holds 55 patents in countries such as the United Kingdom, Italy, Germany, France, Spain, the United States, South Korea, Australia and Brazil. All patents owned or applied by the company are related to the technologies involved in the company's products or products under development, and the company's patents are independently developed by the internal R&D team. Specifically, as of the same date, the company has 8 patents and 3 patent applications related to the core product VitaFlowTM II and the first commercial TAVI product VitaFlowTM. In addition, as of the Latest Practicable Date, the EPO had received objections filed by third parties against one of the patents of the Company's TAVI products.</p><p>According to the financial information, the revenue in 2019 was RMB21.502 million and the revenue in the first seven months of 2020 was RMB48.44 million; The loss for the year from 2018 to 2019 was RMB60.263 million and RMB145 million, respectively, and the loss for the first seven months of 2020 was approximately RMB193 million.</p><p><img src=\"https://static.tigerbbs.com/fc00861b0abac48713294c0bed8add63\" tg-width=\"895\" tg-height=\"237\" referrerpolicy=\"no-referrer\"></p><p>According to the announcement, the net loss was mainly attributable to large R&D costs. In addition, the net loss is also attributable to other operating costs, such as distribution costs, administrative expenses, and changes in fair value of financial instruments. The Company expects to continue to incur net losses in the near future as the Company strives to advance research and development activities, continue to develop product candidates, seek regulatory approvals and commercialization of product candidates.</p><p>According to the Prospectus, the Company has entered into the Cornerstone Investment Agreement with the Cornerstone Investors and the Cornerstone Investors have agreed to subscribe, subject to certain conditions, for the relevant number of Offer Shares available for purchase in an aggregate amount of approximately HK$969 million at the Offer Price. Cornerstone investors include: CPE Fund, Hillhouse Funds., Lake Bleu Prime, GIC, Taikang Life , Snow Lake Funds, Yi Fang Da Brocade, CDG, Indus Funds, Woodline Fund, 3W Fund, Tybourne Funds, WT Funds, China Asset Management, PinPoint and Kunlun.</p><p><img src=\"https://static.tigerbbs.com/8e847396fccbbe753f14e11f19c0b0a8\" tg-width=\"914\" tg-height=\"553\" referrerpolicy=\"no-referrer\"></p><p>Assuming an Offer Price of HK$11.65 per Share, the net raise from the Global Offering is estimated to be approximately HK$2,247.5 million. 30.0% will be allocated to the core product VitaFlowTM II, 3.4% will be allocated to the first commercialized TAVI product VitaFlowTM, and 27.0% will be allocated to other products in the existing product pipeline; 15.0% will be used to fund the expansion of our product portfolio through, among other things, mergers and acquisitions, license-in arrangements or equity investments with global enablers, including medical device companies and research institutions, 14.6% will be used to expand production capacity and enhance the capacity to produce VitaFlow™ and VitaFlow™ II, and 10.0% will be allocated for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-01-26 07:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On January 26,<a href=\"https://laohu8.com/S/02160\">Xintong Medical-B</a>In the IPO from 26 to 29 January 2021, the Company intends to offer approximately 205.6 million shares globally, representing 10% of the Hong Kong Offer Shares, 90% of the International Offer Shares, and a 15% over-allotment option. It is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on 4 February 2021.</p><p><b>The new channel of Tiger Securities is expected to open at 14: 00 noon:</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Create a new entry</b></a></p><p><img src=\"https://static.tigerbbs.com/693c26afc147ec7fa1ebdb4eb1a1ebe8\" tg-width=\"967\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has a lot of 1,000 shares and an admission fee of approximately HK$12,322.94.</p><p>Group B has 450,000 shares, and the funds required for subscription are about HK$5,545,322.73.</p><p><img src=\"https://static.tigerbbs.com/38e952a41dfccdab7697b55b35f4cacf\" tg-width=\"1126\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p>The company is a Chinese medical device company focused on the R&D and commercialization of innovative transcatheter and surgical solutions in the field of heart valve diseases. The company's mission is to continue to innovate and provide patients with heart valve disease with the best inclusive healthcare solutions that can improve their quality of life.</p><p>The company's self-developed first-generation transcatheter aortic valve implantation (TAVI) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. The second-generation TAVI product, VitaFlowTM II, has completed registration clinical trials in China and is undergoing clinical trials in Europe. The company submitted the registration application for VitaFlowTM II to the NMPA in October 2020. The application was accepted by the NMPA in November 2020 and is currently under review. It is currently expected to complete the registration of VitaFlowTM II in China by the end of 2021. Separately, the company plans to apply for the CE marking of VitaFlowTM II by the end of 2021. According to Frost & Sullivan, as of the Latest Practicable Date, VitaFlow™ II was the only TAVI product that was developed in China and has commenced clinical trials in Europe.</p><p>As of the Latest Practicable Date, the Company owned 98 patents in China, including 23 invention patents, 68 utility model patents and 7 industrial designs. As of the same date, there were also 82 pending patent applications in China, including 72 invention patents and 10 utility model patents. To promote the Company's strategy to enter overseas markets, it also holds 55 patents in countries such as the United Kingdom, Italy, Germany, France, Spain, the United States, South Korea, Australia and Brazil. All patents owned or applied by the company are related to the technologies involved in the company's products or products under development, and the company's patents are independently developed by the internal R&D team. Specifically, as of the same date, the company has 8 patents and 3 patent applications related to the core product VitaFlowTM II and the first commercial TAVI product VitaFlowTM. In addition, as of the Latest Practicable Date, the EPO had received objections filed by third parties against one of the patents of the Company's TAVI products.</p><p>According to the financial information, the revenue in 2019 was RMB21.502 million and the revenue in the first seven months of 2020 was RMB48.44 million; The loss for the year from 2018 to 2019 was RMB60.263 million and RMB145 million, respectively, and the loss for the first seven months of 2020 was approximately RMB193 million.</p><p><img src=\"https://static.tigerbbs.com/fc00861b0abac48713294c0bed8add63\" tg-width=\"895\" tg-height=\"237\" referrerpolicy=\"no-referrer\"></p><p>According to the announcement, the net loss was mainly attributable to large R&D costs. In addition, the net loss is also attributable to other operating costs, such as distribution costs, administrative expenses, and changes in fair value of financial instruments. The Company expects to continue to incur net losses in the near future as the Company strives to advance research and development activities, continue to develop product candidates, seek regulatory approvals and commercialization of product candidates.</p><p>According to the Prospectus, the Company has entered into the Cornerstone Investment Agreement with the Cornerstone Investors and the Cornerstone Investors have agreed to subscribe, subject to certain conditions, for the relevant number of Offer Shares available for purchase in an aggregate amount of approximately HK$969 million at the Offer Price. Cornerstone investors include: CPE Fund, Hillhouse Funds., Lake Bleu Prime, GIC, Taikang Life , Snow Lake Funds, Yi Fang Da Brocade, CDG, Indus Funds, Woodline Fund, 3W Fund, Tybourne Funds, WT Funds, China Asset Management, PinPoint and Kunlun.</p><p><img src=\"https://static.tigerbbs.com/8e847396fccbbe753f14e11f19c0b0a8\" tg-width=\"914\" tg-height=\"553\" referrerpolicy=\"no-referrer\"></p><p>Assuming an Offer Price of HK$11.65 per Share, the net raise from the Global Offering is estimated to be approximately HK$2,247.5 million. 30.0% will be allocated to the core product VitaFlowTM II, 3.4% will be allocated to the first commercialized TAVI product VitaFlowTM, and 27.0% will be allocated to other products in the existing product pipeline; 15.0% will be used to fund the expansion of our product portfolio through, among other things, mergers and acquisitions, license-in arrangements or equity investments with global enablers, including medical device companies and research institutions, 14.6% will be used to expand production capacity and enhance the capacity to produce VitaFlow™ and VitaFlow™ II, and 10.0% will be allocated for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"02160":"微创心通-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163889952","content_text":"1月26日，心通医疗-B于2021年1月26日-29日招股，公司拟全球发售约2.056亿股，香港发售股份占10%，国际发售股份占90%，另有15%超额配股权。每股11.1-12.2港元，每手1000股，预期股份将于2021年2月4日上午九时正开始在联交所买卖。老虎证券打新通道预计中午14：00开放：打新入口申购阶梯：甲组每手1000股，入场费约12322.94港元。乙组头为45万股，申购所需资金约5545322.73港元。该公司是一家中国医疗器械企业，专注于心脏瓣膜疾病领域创新的经导管及手术解决方案的研发和商业化。公司的使命是持续创新，为心脏瓣膜疾病患者提供能改善其生活质量的最佳普惠医疗解决方案。该公司自主研发的第一代经导管主动脉瓣植入(TAVI)产品VitaFlowTM，于2019年7 月获国家药监局审批并随后于2019年8月在中国进行商业化。第二代TAVI产品VitaFlowTM II已在中国完成注册临床试验且正在欧洲进行临床试验。公司于2020年10月向国家药监局提交VitaFlowTM II的注册申请。该申请于2020年11月获国家药监局受理且目前正在审核中。目前预计将于2021年底前在中国完成VitaFlowTM II的注册。另外，公司计划于2021年底前申请VitaFlowTM II的CE标志。根据弗若斯特沙利文的资料，截至最后可行日期，VitaFlowTM II是唯一在中国研发并已在欧洲开展临床试验的TAVI产品。截至最后可行日期，公司在中国拥有98项专利，包括23项发明专利、68项实用新型专利和7项工业设计。截至同日，亦在中国拥有82项待批核的专利申请，包括72项发明专利及10项实用新型专利。为推动公司进入海外市场的策略，亦在英国、意大利、德国、法国、西班牙、美国、韩国、澳大利亚及巴西等国家拥有55项专利。公司拥有或申请的所有专利均与公司的产品或在研产品涉及的技术相关，公司的专利均由内部研发团队自主研发。具体而言，截至同日，公司拥有与核心产品VitaFlowTM II和首款商业化TAVI产品VitaFlowTM有关的8项专利及3项专利申请。此外，截至最后可行日期，欧洲专利局已收到第三方对公司TAVI产品其中一项专利提起的异议。财务资料显示，于2019年收入为人民币2150.2万元，2020年前7个月收入为人民币4844万元;2018年-2019年年内亏损分别为6026.3万元、1.45亿元，2020年首7个月亏损为约1.93亿元。公告称，净亏损主要归因于大额研发成本。此外，净亏损亦归因于其他经营成本，如分销成本、行政开支，以及金融工具公允价值变动。随着公司努力推进研发活动、持续开发在研产品、寻求在研产品监管批准及商业化，公司预计于不久的将来继续产生净亏损。招股书显示，公司已与基石投资者订立基石投资协议，基石投资者已同意在若干条件的规限下按发售价认购总金额约9.69亿港元可购买的有关数目的发售股份。基石投资者包括：CPE Fund、Hillhouse Funds.、Lake Bleu Prime、GIC、泰康人寿、Snow Lake Funds、Yi Fang Da Brocade、CDG、Indus Funds、Woodline Fund、3W Fund、Tybourne Funds、WT Funds、华夏基金、PinPoint及昆仑。假设发售价为每股股份11.65港元，估计全球发售净筹约22.475亿港元。30.0%将被分配予核心产品VitaFlowTM II，3.4%将被分配予首款商业化TAVI产品 VitaFlowTM，27.0%将被分配予现有产品管线的其他产品;15.0%将用于为通过(其中包括)併购、授权引进安排或股权投资与包括医疗器械企业及研究机构在内的全球赋能者合作扩展我们的产品组合提供资金，14.6%将用于扩大产能并提高生产VitaFlowTM 及VitaFlowTM II的能力，10.0%将分配作营运资金及一般公司用途。","news_type":1,"symbols_score_info":{"02160":0.9}},"isVote":1,"tweetType":1,"viewCount":4159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":319157339,"gmtCreate":1611558436621,"gmtModify":1704860692856,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Good good","listText":"Good good","text":"Good good","images":[{"img":"https://static.tigerbbs.com/a494df014c3d4340cef358fe375f5749","width":"1080","height":"2256"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319157339","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":319996371,"gmtCreate":1611461004493,"gmtModify":1704860340222,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319996371","repostId":"2105491904","repostType":4,"repost":{"id":"2105491904","kind":"news","pubTimestamp":1611359026,"share":"https://ttm.financial/m/news/2105491904?lang=en_US&edition=fundamental","pubTime":"2021-01-23 07:43","market":"us","language":"zh","title":"Baidu intends to split 80 shares of 1 ordinary share, corresponding to HK$244.9 per share in Hong Kong shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2105491904","media":"新浪港股","summary":"1月23日消息，百度发布报告，百多昨日宣布，将于北京时间2021年3月1日上午11点在北京市海淀区上地十街10号召开特别股东大会。在本次股东大会上，公司将对每股A类股、B类股以及优先股拆分成80），供特别股东大会审议和表决。百度董事会已批准调整美国存托股（ADS）与拆分后的普通股的兑换比率，从之前的10股ADS代表1股A类普通股，调整为1股ADS代表8股A类普通股。该调整将于2021年3月1日生效。当然，其前提是股东批准1：80的拆分提议。截至昨日收盘，百度每ADS价格为252.75美元，对应每股价格2527.5美元；拆分后，每股价格为31.59375美元，折合每股244.9港元。","content":"<p>January 23rd news,<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>Release of the report, Baiduo announced yesterday that it will hold a special shareholders' meeting at 11: 00 a.m. on March 1, 2021, Beijing time, at No.10 Shangdi 10th Street, Haidian District, Beijing. At this general meeting, the Company will split each Class A share, Class B share and preferred shares into 80) for consideration and voting at the extraordinary general meeting.</p><p>Baidu's board of directors has approved an adjustment to the conversion ratio of American Depositary Shares (ADS) to split common shares from the previous 10 ADS shares representing 1 Class A common share to 1 ADS share representing 8 Class A common shares. The adjustment will take effect on March 1, 2021. The premise, of course, is that shareholders approve the 1:80 split proposal.</p><p>As of yesterday's close, Baidu's price per ADS was $252.75, corresponding to a price per share of $2527.5; After the split, the price per share was $31.59375, equivalent to HK$244.9 per share.</p><p><img src=\"https://static.tigerbbs.com/192e4c4a3f37d4ffd14550014fcfc831\" tg-width=\"550\" tg-height=\"334\"></p>","source":"highlight_sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu intends to split 80 shares of 1 ordinary share, corresponding to HK$244.9 per share in Hong Kong shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu intends to split 80 shares of 1 ordinary share, corresponding to HK$244.9 per share in Hong Kong shares\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2021-01-23 07:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p>January 23rd news,<a href=\"https://laohu8.com/S/BIDU\">Baidu</a>Release of the report, Baiduo announced yesterday that it will hold a special shareholders' meeting at 11: 00 a.m. on March 1, 2021, Beijing time, at No.10 Shangdi 10th Street, Haidian District, Beijing. At this general meeting, the Company will split each Class A share, Class B share and preferred shares into 80) for consideration and voting at the extraordinary general meeting.</p><p>Baidu's board of directors has approved an adjustment to the conversion ratio of American Depositary Shares (ADS) to split common shares from the previous 10 ADS shares representing 1 Class A common share to 1 ADS share representing 8 Class A common shares. The adjustment will take effect on March 1, 2021. The premise, of course, is that shareholders approve the 1:80 split proposal.</p><p>As of yesterday's close, Baidu's price per ADS was $252.75, corresponding to a price per share of $2527.5; After the split, the price per share was $31.59375, equivalent to HK$244.9 per share.</p><p><img src=\"https://static.tigerbbs.com/192e4c4a3f37d4ffd14550014fcfc831\" tg-width=\"550\" tg-height=\"334\"></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/hkstock/hkstocknews/2021-01-23/doc-ikftssan9833668.shtml\">新浪港股</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9c9083ea560ad849832bc28e4921bb34","relate_stocks":{"BIDU":"百度"},"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/hkstock/hkstocknews/2021-01-23/doc-ikftssan9833668.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2105491904","content_text":"1月23日消息，百度发布报告，百多昨日宣布，将于北京时间2021年3月1日上午11点在北京市海淀区上地十街10号召开特别股东大会。在本次股东大会上，公司将对每股A类股、B类股以及优先股拆分成80），供特别股东大会审议和表决。百度董事会已批准调整美国存托股（ADS）与拆分后的普通股的兑换比率，从之前的10股ADS代表1股A类普通股，调整为1股ADS代表8股A类普通股。该调整将于2021年3月1日生效。当然，其前提是股东批准1：80的拆分提议。截至昨日收盘，百度每ADS价格为252.75美元，对应每股价格2527.5美元；拆分后，每股价格为31.59375美元，折合每股244.9港元。","news_type":1,"symbols_score_info":{"BIDU":0.9}},"isVote":1,"tweetType":1,"viewCount":901,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":310722671,"gmtCreate":1611379034593,"gmtModify":1704860138839,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Wwwwww","listText":"Wwwwww","text":"Wwwwww","images":[{"img":"https://static.tigerbbs.com/59a33db5bc759d53141625fffeb81631","width":"1080","height":"1202"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/310722671","isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":310783080,"gmtCreate":1611372391640,"gmtModify":1704860107059,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a>k","listText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a>k","text":"$Bit Digital,Inc(BTBT)$k","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/310783080","isVote":1,"tweetType":1,"viewCount":796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":310783080,"gmtCreate":1611372391640,"gmtModify":1704860107059,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a>k","listText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a>k","text":"$Bit Digital,Inc(BTBT)$k","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/310783080","isVote":1,"tweetType":1,"viewCount":796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114194503,"gmtCreate":1623055913802,"gmtModify":1704195136827,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"ru is unit","listText":"ru is unit","text":"ru is unit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114194503","repostId":"1182426186","repostType":4,"isVote":1,"tweetType":1,"viewCount":2818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313561335,"gmtCreate":1611739584827,"gmtModify":1704862510471,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":".......","listText":".......","text":".......","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313561335","repostId":"1150077403","repostType":4,"isVote":1,"tweetType":1,"viewCount":3736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":319782582,"gmtCreate":1611623647346,"gmtModify":1704861439547,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319782582","repostId":"1163889952","repostType":4,"repost":{"id":"1163889952","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611616215,"share":"https://ttm.financial/m/news/1163889952?lang=en_US&edition=fundamental","pubTime":"2021-01-26 07:10","market":"hk","language":"zh","title":"Xintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94","url":"https://stock-news.laohu8.com/highlight/detail?id=1163889952","media":"老虎资讯综合","summary":"1月26日，心通医疗-B于2021年1月26日-29日招股，公司拟全球发售约2.056亿股，香港发售股份占10%，国际发售股份占90%，另有15%超额配股权。每股11.1-12.2港元，每手1000股","content":"<p>On January 26,<a href=\"https://laohu8.com/S/02160\">Xintong Medical-B</a>In the IPO from 26 to 29 January 2021, the Company intends to offer approximately 205.6 million shares globally, representing 10% of the Hong Kong Offer Shares, 90% of the International Offer Shares, and a 15% over-allotment option. It is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on 4 February 2021.</p><p><b>The new channel of Tiger Securities is expected to open at 14: 00 noon:</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Create a new entry</b></a></p><p><img src=\"https://static.tigerbbs.com/693c26afc147ec7fa1ebdb4eb1a1ebe8\" tg-width=\"967\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has a lot of 1,000 shares and an admission fee of approximately HK$12,322.94.</p><p>Group B has 450,000 shares, and the funds required for subscription are about HK$5,545,322.73.</p><p><img src=\"https://static.tigerbbs.com/38e952a41dfccdab7697b55b35f4cacf\" tg-width=\"1126\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p>The company is a Chinese medical device company focused on the R&D and commercialization of innovative transcatheter and surgical solutions in the field of heart valve diseases. The company's mission is to continue to innovate and provide patients with heart valve disease with the best inclusive healthcare solutions that can improve their quality of life.</p><p>The company's self-developed first-generation transcatheter aortic valve implantation (TAVI) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. The second-generation TAVI product, VitaFlowTM II, has completed registration clinical trials in China and is undergoing clinical trials in Europe. The company submitted the registration application for VitaFlowTM II to the NMPA in October 2020. The application was accepted by the NMPA in November 2020 and is currently under review. It is currently expected to complete the registration of VitaFlowTM II in China by the end of 2021. Separately, the company plans to apply for the CE marking of VitaFlowTM II by the end of 2021. According to Frost & Sullivan, as of the Latest Practicable Date, VitaFlow™ II was the only TAVI product that was developed in China and has commenced clinical trials in Europe.</p><p>As of the Latest Practicable Date, the Company owned 98 patents in China, including 23 invention patents, 68 utility model patents and 7 industrial designs. As of the same date, there were also 82 pending patent applications in China, including 72 invention patents and 10 utility model patents. To promote the Company's strategy to enter overseas markets, it also holds 55 patents in countries such as the United Kingdom, Italy, Germany, France, Spain, the United States, South Korea, Australia and Brazil. All patents owned or applied by the company are related to the technologies involved in the company's products or products under development, and the company's patents are independently developed by the internal R&D team. Specifically, as of the same date, the company has 8 patents and 3 patent applications related to the core product VitaFlowTM II and the first commercial TAVI product VitaFlowTM. In addition, as of the Latest Practicable Date, the EPO had received objections filed by third parties against one of the patents of the Company's TAVI products.</p><p>According to the financial information, the revenue in 2019 was RMB21.502 million and the revenue in the first seven months of 2020 was RMB48.44 million; The loss for the year from 2018 to 2019 was RMB60.263 million and RMB145 million, respectively, and the loss for the first seven months of 2020 was approximately RMB193 million.</p><p><img src=\"https://static.tigerbbs.com/fc00861b0abac48713294c0bed8add63\" tg-width=\"895\" tg-height=\"237\" referrerpolicy=\"no-referrer\"></p><p>According to the announcement, the net loss was mainly attributable to large R&D costs. In addition, the net loss is also attributable to other operating costs, such as distribution costs, administrative expenses, and changes in fair value of financial instruments. The Company expects to continue to incur net losses in the near future as the Company strives to advance research and development activities, continue to develop product candidates, seek regulatory approvals and commercialization of product candidates.</p><p>According to the Prospectus, the Company has entered into the Cornerstone Investment Agreement with the Cornerstone Investors and the Cornerstone Investors have agreed to subscribe, subject to certain conditions, for the relevant number of Offer Shares available for purchase in an aggregate amount of approximately HK$969 million at the Offer Price. Cornerstone investors include: CPE Fund, Hillhouse Funds., Lake Bleu Prime, GIC, Taikang Life , Snow Lake Funds, Yi Fang Da Brocade, CDG, Indus Funds, Woodline Fund, 3W Fund, Tybourne Funds, WT Funds, China Asset Management, PinPoint and Kunlun.</p><p><img src=\"https://static.tigerbbs.com/8e847396fccbbe753f14e11f19c0b0a8\" tg-width=\"914\" tg-height=\"553\" referrerpolicy=\"no-referrer\"></p><p>Assuming an Offer Price of HK$11.65 per Share, the net raise from the Global Offering is estimated to be approximately HK$2,247.5 million. 30.0% will be allocated to the core product VitaFlowTM II, 3.4% will be allocated to the first commercialized TAVI product VitaFlowTM, and 27.0% will be allocated to other products in the existing product pipeline; 15.0% will be used to fund the expansion of our product portfolio through, among other things, mergers and acquisitions, license-in arrangements or equity investments with global enablers, including medical device companies and research institutions, 14.6% will be used to expand production capacity and enhance the capacity to produce VitaFlow™ and VitaFlow™ II, and 10.0% will be allocated for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXintong Medical-B starts its IPO today, with an admission fee of approximately HK$12,322.94\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-01-26 07:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On January 26,<a href=\"https://laohu8.com/S/02160\">Xintong Medical-B</a>In the IPO from 26 to 29 January 2021, the Company intends to offer approximately 205.6 million shares globally, representing 10% of the Hong Kong Offer Shares, 90% of the International Offer Shares, and a 15% over-allotment option. It is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on 4 February 2021.</p><p><b>The new channel of Tiger Securities is expected to open at 14: 00 noon:</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Create a new entry</b></a></p><p><img src=\"https://static.tigerbbs.com/693c26afc147ec7fa1ebdb4eb1a1ebe8\" tg-width=\"967\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has a lot of 1,000 shares and an admission fee of approximately HK$12,322.94.</p><p>Group B has 450,000 shares, and the funds required for subscription are about HK$5,545,322.73.</p><p><img src=\"https://static.tigerbbs.com/38e952a41dfccdab7697b55b35f4cacf\" tg-width=\"1126\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p>The company is a Chinese medical device company focused on the R&D and commercialization of innovative transcatheter and surgical solutions in the field of heart valve diseases. The company's mission is to continue to innovate and provide patients with heart valve disease with the best inclusive healthcare solutions that can improve their quality of life.</p><p>The company's self-developed first-generation transcatheter aortic valve implantation (TAVI) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. The second-generation TAVI product, VitaFlowTM II, has completed registration clinical trials in China and is undergoing clinical trials in Europe. The company submitted the registration application for VitaFlowTM II to the NMPA in October 2020. The application was accepted by the NMPA in November 2020 and is currently under review. It is currently expected to complete the registration of VitaFlowTM II in China by the end of 2021. Separately, the company plans to apply for the CE marking of VitaFlowTM II by the end of 2021. According to Frost & Sullivan, as of the Latest Practicable Date, VitaFlow™ II was the only TAVI product that was developed in China and has commenced clinical trials in Europe.</p><p>As of the Latest Practicable Date, the Company owned 98 patents in China, including 23 invention patents, 68 utility model patents and 7 industrial designs. As of the same date, there were also 82 pending patent applications in China, including 72 invention patents and 10 utility model patents. To promote the Company's strategy to enter overseas markets, it also holds 55 patents in countries such as the United Kingdom, Italy, Germany, France, Spain, the United States, South Korea, Australia and Brazil. All patents owned or applied by the company are related to the technologies involved in the company's products or products under development, and the company's patents are independently developed by the internal R&D team. Specifically, as of the same date, the company has 8 patents and 3 patent applications related to the core product VitaFlowTM II and the first commercial TAVI product VitaFlowTM. In addition, as of the Latest Practicable Date, the EPO had received objections filed by third parties against one of the patents of the Company's TAVI products.</p><p>According to the financial information, the revenue in 2019 was RMB21.502 million and the revenue in the first seven months of 2020 was RMB48.44 million; The loss for the year from 2018 to 2019 was RMB60.263 million and RMB145 million, respectively, and the loss for the first seven months of 2020 was approximately RMB193 million.</p><p><img src=\"https://static.tigerbbs.com/fc00861b0abac48713294c0bed8add63\" tg-width=\"895\" tg-height=\"237\" referrerpolicy=\"no-referrer\"></p><p>According to the announcement, the net loss was mainly attributable to large R&D costs. In addition, the net loss is also attributable to other operating costs, such as distribution costs, administrative expenses, and changes in fair value of financial instruments. The Company expects to continue to incur net losses in the near future as the Company strives to advance research and development activities, continue to develop product candidates, seek regulatory approvals and commercialization of product candidates.</p><p>According to the Prospectus, the Company has entered into the Cornerstone Investment Agreement with the Cornerstone Investors and the Cornerstone Investors have agreed to subscribe, subject to certain conditions, for the relevant number of Offer Shares available for purchase in an aggregate amount of approximately HK$969 million at the Offer Price. Cornerstone investors include: CPE Fund, Hillhouse Funds., Lake Bleu Prime, GIC, Taikang Life , Snow Lake Funds, Yi Fang Da Brocade, CDG, Indus Funds, Woodline Fund, 3W Fund, Tybourne Funds, WT Funds, China Asset Management, PinPoint and Kunlun.</p><p><img src=\"https://static.tigerbbs.com/8e847396fccbbe753f14e11f19c0b0a8\" tg-width=\"914\" tg-height=\"553\" referrerpolicy=\"no-referrer\"></p><p>Assuming an Offer Price of HK$11.65 per Share, the net raise from the Global Offering is estimated to be approximately HK$2,247.5 million. 30.0% will be allocated to the core product VitaFlowTM II, 3.4% will be allocated to the first commercialized TAVI product VitaFlowTM, and 27.0% will be allocated to other products in the existing product pipeline; 15.0% will be used to fund the expansion of our product portfolio through, among other things, mergers and acquisitions, license-in arrangements or equity investments with global enablers, including medical device companies and research institutions, 14.6% will be used to expand production capacity and enhance the capacity to produce VitaFlow™ and VitaFlow™ II, and 10.0% will be allocated for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"02160":"微创心通-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163889952","content_text":"1月26日，心通医疗-B于2021年1月26日-29日招股，公司拟全球发售约2.056亿股，香港发售股份占10%，国际发售股份占90%，另有15%超额配股权。每股11.1-12.2港元，每手1000股，预期股份将于2021年2月4日上午九时正开始在联交所买卖。老虎证券打新通道预计中午14：00开放：打新入口申购阶梯：甲组每手1000股，入场费约12322.94港元。乙组头为45万股，申购所需资金约5545322.73港元。该公司是一家中国医疗器械企业，专注于心脏瓣膜疾病领域创新的经导管及手术解决方案的研发和商业化。公司的使命是持续创新，为心脏瓣膜疾病患者提供能改善其生活质量的最佳普惠医疗解决方案。该公司自主研发的第一代经导管主动脉瓣植入(TAVI)产品VitaFlowTM，于2019年7 月获国家药监局审批并随后于2019年8月在中国进行商业化。第二代TAVI产品VitaFlowTM II已在中国完成注册临床试验且正在欧洲进行临床试验。公司于2020年10月向国家药监局提交VitaFlowTM II的注册申请。该申请于2020年11月获国家药监局受理且目前正在审核中。目前预计将于2021年底前在中国完成VitaFlowTM II的注册。另外，公司计划于2021年底前申请VitaFlowTM II的CE标志。根据弗若斯特沙利文的资料，截至最后可行日期，VitaFlowTM II是唯一在中国研发并已在欧洲开展临床试验的TAVI产品。截至最后可行日期，公司在中国拥有98项专利，包括23项发明专利、68项实用新型专利和7项工业设计。截至同日，亦在中国拥有82项待批核的专利申请，包括72项发明专利及10项实用新型专利。为推动公司进入海外市场的策略，亦在英国、意大利、德国、法国、西班牙、美国、韩国、澳大利亚及巴西等国家拥有55项专利。公司拥有或申请的所有专利均与公司的产品或在研产品涉及的技术相关，公司的专利均由内部研发团队自主研发。具体而言，截至同日，公司拥有与核心产品VitaFlowTM II和首款商业化TAVI产品VitaFlowTM有关的8项专利及3项专利申请。此外，截至最后可行日期，欧洲专利局已收到第三方对公司TAVI产品其中一项专利提起的异议。财务资料显示，于2019年收入为人民币2150.2万元，2020年前7个月收入为人民币4844万元;2018年-2019年年内亏损分别为6026.3万元、1.45亿元，2020年首7个月亏损为约1.93亿元。公告称，净亏损主要归因于大额研发成本。此外，净亏损亦归因于其他经营成本，如分销成本、行政开支，以及金融工具公允价值变动。随着公司努力推进研发活动、持续开发在研产品、寻求在研产品监管批准及商业化，公司预计于不久的将来继续产生净亏损。招股书显示，公司已与基石投资者订立基石投资协议，基石投资者已同意在若干条件的规限下按发售价认购总金额约9.69亿港元可购买的有关数目的发售股份。基石投资者包括：CPE Fund、Hillhouse Funds.、Lake Bleu Prime、GIC、泰康人寿、Snow Lake Funds、Yi Fang Da Brocade、CDG、Indus Funds、Woodline Fund、3W Fund、Tybourne Funds、WT Funds、华夏基金、PinPoint及昆仑。假设发售价为每股股份11.65港元，估计全球发售净筹约22.475亿港元。30.0%将被分配予核心产品VitaFlowTM II，3.4%将被分配予首款商业化TAVI产品 VitaFlowTM，27.0%将被分配予现有产品管线的其他产品;15.0%将用于为通过(其中包括)併购、授权引进安排或股权投资与包括医疗器械企业及研究机构在内的全球赋能者合作扩展我们的产品组合提供资金，14.6%将用于扩大产能并提高生产VitaFlowTM 及VitaFlowTM II的能力，10.0%将分配作营运资金及一般公司用途。","news_type":1,"symbols_score_info":{"02160":0.9}},"isVote":1,"tweetType":1,"viewCount":4159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":310722671,"gmtCreate":1611379034593,"gmtModify":1704860138839,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Wwwwww","listText":"Wwwwww","text":"Wwwwww","images":[{"img":"https://static.tigerbbs.com/59a33db5bc759d53141625fffeb81631","width":"1080","height":"1202"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/310722671","isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380962894,"gmtCreate":1612505159518,"gmtModify":1704872100089,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyy","listText":"Yyy","text":"Yyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380962894","repostId":"1194873125","repostType":4,"repost":{"id":"1194873125","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1612484798,"share":"https://ttm.financial/m/news/1194873125?lang=en_US&edition=fundamental","pubTime":"2021-02-05 08:26","market":"hk","language":"zh","title":"Nuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33","url":"https://stock-news.laohu8.com/highlight/detail?id=1194873125","media":"老虎资讯综合","summary":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至","content":"<p>February 5th news,<a href=\"https://laohu8.com/S/06606\">NovoHealth-B</a>To announce the details of the prospectus, it is planned to issue 76,598 million shares, of which approximately 90%, or approximately 68,938 million shares, are under international placing and approximately 10%, or approximately 7,66 million shares, are under local public offering, with an over-allotment option of 15%. The offering price ranged from $22.7 to $26.66 per share, raising up to approximately $2.042 billion. Before handling fee, the entrance fee for each board lot of 500 shares is approximately HK$13,464.33. The company will be listed from today (February 5th) to next Wednesday (10th), and it is expected to be listed on February 18th. The joint sponsors of the company are Goldman Sachs and UBS.</p><p><b>The new channel of Tiger Play opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go to new <<<</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health, established in November 2015, is a pioneer in China's colorectal cancer screening market, aiming to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Changweiqing, is the first and only molecular cancer screening test product approved by the NMPA in China. The company focuses on designing, developing and commercializing cancer screening tests, and its two home-based colorectal cancer screening testing products, Changweiqing and Pupu Tube, collaboratively deal with target populations with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of financial position,</b>During FY2018-2019, the Company recorded total revenue of HK$18.816 million and HK$58.275 million respectively, representing a year-on-year increase of 209.7%, and net losses of HK$224.9 million and HK$106.5 million respectively for the same period. For the first nine months ended 30 September 2019 and 2020, total revenue was HK$35.44 million and HK$35.309 million, respectively, and net loss was HK$62.508 million and HK$530 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of industry,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, representing a CAGR of 3.2%. According to Frost & Sullivan, the cost of treating colorectal cancer imposes a heavy economic burden on the healthcare system in China, with the overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few types of cancer for which regular screening is recommended in the medium-risk population without signs or symptoms of cancer due to its high incidence, high mortality, long tumor development cycle, and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available at the Offer Price, totaling approximately US$124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Clear Pool Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the Company intends to</b></p><p><ul><li>Approximately 40% of which was used to finance the commercialization and further development of the product \"Changweiqing\";</li><li>Approximately 30% is used to fund ongoing and planned early-stage pipeline product research and development; Approximately 15% will be used for potential acquisitions or external introduction of product candidates in the cancer screening field;</li><li>Approximately 5% was used to fund the ongoing sales and marketing of the product \"Pupu Tube\";</li><li>and approximately 10% for general working capital.</li></ul></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuohui Health starts its IPO today, with an admission fee of approximately HK$13,464.33\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-05 08:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 5th news,<a href=\"https://laohu8.com/S/06606\">NovoHealth-B</a>To announce the details of the prospectus, it is planned to issue 76,598 million shares, of which approximately 90%, or approximately 68,938 million shares, are under international placing and approximately 10%, or approximately 7,66 million shares, are under local public offering, with an over-allotment option of 15%. The offering price ranged from $22.7 to $26.66 per share, raising up to approximately $2.042 billion. Before handling fee, the entrance fee for each board lot of 500 shares is approximately HK$13,464.33. The company will be listed from today (February 5th) to next Wednesday (10th), and it is expected to be listed on February 18th. The joint sponsors of the company are Goldman Sachs and UBS.</p><p><b>The new channel of Tiger Play opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go to new <<<</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health, established in November 2015, is a pioneer in China's colorectal cancer screening market, aiming to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Changweiqing, is the first and only molecular cancer screening test product approved by the NMPA in China. The company focuses on designing, developing and commercializing cancer screening tests, and its two home-based colorectal cancer screening testing products, Changweiqing and Pupu Tube, collaboratively deal with target populations with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of financial position,</b>During FY2018-2019, the Company recorded total revenue of HK$18.816 million and HK$58.275 million respectively, representing a year-on-year increase of 209.7%, and net losses of HK$224.9 million and HK$106.5 million respectively for the same period. For the first nine months ended 30 September 2019 and 2020, total revenue was HK$35.44 million and HK$35.309 million, respectively, and net loss was HK$62.508 million and HK$530 million, respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of industry,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, representing a CAGR of 3.2%. According to Frost & Sullivan, the cost of treating colorectal cancer imposes a heavy economic burden on the healthcare system in China, with the overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few types of cancer for which regular screening is recommended in the medium-risk population without signs or symptoms of cancer due to its high incidence, high mortality, long tumor development cycle, and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>In terms of cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available at the Offer Price, totaling approximately US$124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Clear Pool Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the Company intends to</b></p><p><ul><li>Approximately 40% of which was used to finance the commercialization and further development of the product \"Changweiqing\";</li><li>Approximately 30% is used to fund ongoing and planned early-stage pipeline product research and development; Approximately 15% will be used for potential acquisitions or external introduction of product candidates in the cancer screening field;</li><li>Approximately 5% was used to fund the ongoing sales and marketing of the product \"Pupu Tube\";</li><li>and approximately 10% for general working capital.</li></ul></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194873125","content_text":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至26.66元，集资最多约20.42亿元。未计手续费，每手500股入场费约13,464.33港元。该公司将于今日（2月5日）起至下周三(10日)招股，预期2月18日挂牌上市。公司联席保荐人为高盛、瑞银。老虎打新通道今天中午11:30开通！去打新<<<据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约1.24亿美元，包括：Invesco Advisers, Inc、Lake Bleu Prime Healthcare Master Fund Limited、清池资本、GIC 、南方基金等。筹资用途方面，公司拟将当中约40%用于为产品「常卫清」的商业化及进一步开发提供资金；约30%用于为正在进行及计划进行的早期阶段管线产品研发提供资金；约15%将用于潜在收购或外部引进癌症筛查领域的候选产品；约5%用于为产品「噗噗管」的持续销售及营销提供资金；以及约10%为一般营运资金。","news_type":1,"symbols_score_info":{"06606":0.9}},"isVote":1,"tweetType":1,"viewCount":3820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312192969,"gmtCreate":1612059853751,"gmtModify":1704867062375,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyyy","listText":"Yyyy","text":"Yyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312192969","repostId":"2107234742","repostType":4,"isVote":1,"tweetType":1,"viewCount":3136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312196465,"gmtCreate":1612059836257,"gmtModify":1704867062052,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyy","listText":"Yyy","text":"Yyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312196465","repostId":"2107223244","repostType":4,"isVote":1,"tweetType":1,"viewCount":3264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312940444,"gmtCreate":1612002519588,"gmtModify":1704866900239,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":"Yyyy","listText":"Yyyy","text":"Yyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/312940444","repostId":"2107408692","repostType":4,"repost":{"id":"2107408692","kind":"highlight","pubTimestamp":1611985051,"share":"https://ttm.financial/m/news/2107408692?lang=en_US&edition=fundamental","pubTime":"2021-01-30 13:37","market":"us","language":"zh","title":"Senior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot","url":"https://stock-news.laohu8.com/highlight/detail?id=2107408692","media":"智通财经网","summary":"美联储高官更担心经济降温，而不是市场过热。","content":"<p>Mary Daly, president of the Federal Reserve Bank of San Francisco, said the U.S. central bank should not prematurely withdraw support for the U.S. economy just because someone made a fortune in the stock market.</p><p>She said Friday in an online discussion moderated by the Stanford Business School that she was more worried about the cooling economy than about the overheating of the stock market.</p><p>She said that the U.S. stock market is running quite well, and many rich people have gained more wealth, but she felt that it can't remove the \"bridge\" and harm people's livelihoods, leaving people without jobs, income and wage growth.</p><p>Daly voted on monetary policy this year. Recently, the market frenzy has pushed the share price of GameStop (GME.US) to skyrocket. Some people have accused the central bank's ultra-loose policy of fueling the bubble in the financial market. However, so far, the U.S. policy layer has not shown a tendency to withdraw easing.</p><p>At its meeting this week, the Fed determined to keep interest rates near zero and reiterated that it would continue to provide massive monetary assistance for some time to come. Federal Reserve Chairman Powell was also asked several times about excessive market speculation. He avoided commenting directly on the GameStop incident, only saying that the financial stability has been moderately fragile recently.</p><p>At a press conference on Wednesday, Powell said that the Fed's ultra-loose monetary policy did not fuel the bubble, and these were not the focus of the Fed. He stressed that the current Fed's monetary policy is \"just right\" and the Fed will continue to maintain its ultra-loose policy until the labor market returns to what the monetary authorities consider to be the maximum employment level; While allowing inflation to exceed the previous target of 2% to make up for past gaps.</p><p>More action could also be taken on asset purchases if necessary, and talk of slowing them is premature at this time, he added.</p>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenior Federal Reserve Officials: Can't End Easing Early Because the Stock Market Is Hot\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经网</strong><span class=\"h-time small\">2021-01-30 13:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Mary Daly, president of the Federal Reserve Bank of San Francisco, said the U.S. central bank should not prematurely withdraw support for the U.S. economy just because someone made a fortune in the stock market.</p><p>She said Friday in an online discussion moderated by the Stanford Business School that she was more worried about the cooling economy than about the overheating of the stock market.</p><p>She said that the U.S. stock market is running quite well, and many rich people have gained more wealth, but she felt that it can't remove the \"bridge\" and harm people's livelihoods, leaving people without jobs, income and wage growth.</p><p>Daly voted on monetary policy this year. Recently, the market frenzy has pushed the share price of GameStop (GME.US) to skyrocket. Some people have accused the central bank's ultra-loose policy of fueling the bubble in the financial market. However, so far, the U.S. policy layer has not shown a tendency to withdraw easing.</p><p>At its meeting this week, the Fed determined to keep interest rates near zero and reiterated that it would continue to provide massive monetary assistance for some time to come. Federal Reserve Chairman Powell was also asked several times about excessive market speculation. He avoided commenting directly on the GameStop incident, only saying that the financial stability has been moderately fragile recently.</p><p>At a press conference on Wednesday, Powell said that the Fed's ultra-loose monetary policy did not fuel the bubble, and these were not the focus of the Fed. He stressed that the current Fed's monetary policy is \"just right\" and the Fed will continue to maintain its ultra-loose policy until the labor market returns to what the monetary authorities consider to be the maximum employment level; While allowing inflation to exceed the previous target of 2% to make up for past gaps.</p><p>More action could also be taken on asset purchases if necessary, and talk of slowing them is premature at this time, he added.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/404125.html\">智通财经网</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/source/image/57164.png?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","PSQ":"做空纳斯达克100指数ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","TQQQ":"纳指三倍做多ETF","UDOW":"三倍做多道指30ETF-ProShares","UPRO":"三倍做多标普500ETF-ProShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares","QID":"两倍做空纳斯达克指数ETF-ProShares","DJX":"1/100道琼斯","SPY":"标普500ETF","OEX":"标普100","SSO":"2倍做多标普500ETF-ProShares","IVV":"标普500ETF-iShares","DXD":"两倍做空道琼30指数ETF-ProShares","QQQ":"纳指100ETF","SDOW":"三倍做空道指30ETF-ProShares",".DJI":"道琼斯","SDS":"两倍做空标普500 ETF-ProShares","OEF":"标普100指数ETF-iShares","SH":"做空标普500-Proshares",".IXIC":"NASDAQ Composite","DOG":"道指ETF-ProShares做空",".SPX":"S&P 500 Index","SQQQ":"纳指三倍做空ETF"},"source_url":"http://www.zhitongcaijing.com/content/detail/404125.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2107408692","content_text":"旧金山联邦储备银行行长Mary Daly说，美国央行不应仅仅因为有人在股市发了财就过早地撤回对美国经济的支持。她本周五在斯坦福大学商学院主持的线上讨论中表示，更担心经济降温，而不是股市过热。她表示，美国股市运行得相当好，许多有钱人获得了更多的财富，但是她觉得不能因此撤走“桥梁”，损害人们的生计，让民众没有工作、没有收入、没有工资增长。Daly今年就货币政策进行了投票。近日，市场的狂热情绪推动GameStop(GME.US)公司股价暴涨，一些人指责央行的超宽松政策助长了金融市场的泡沫，但迄今为止，美国政策层还没有表现出撤回宽松倾向。美联储在本周的会议上确定将利率维持在接近零的水平，并重申将在未来一段时间内继续提供大规模货币援助。美联储主席鲍威尔也数度被问及市场过度投机的问题，他回避了直接评论GameStop事件，只是表示近期金融稳定性出现了些微（moderate）的脆弱。在周三的新闻发布会上，鲍威尔称，美联储的超宽松货币政策没有助长泡沫，这些也不是美联储关注的重点。他强调，目前美联储的货币政策“刚刚好”，美联储将继续维持超宽松政策，直到劳动力市场恢复到货币当局所认为的最大就业水平；同时允许通胀率超过此前2%的目标，以弥补过去的缺口。他补充道，如有必要，还可以在资产购买方面采取更多行动，关于减缓资产购买的讨论目前还为时过早。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"QQQ":0.9,".DJI":0.9,"PSQ":0.9,"MNQmain":0.9,"IVV":0.9,"TQQQ":0.9,"SPY":0.9,"SSO":0.9,"NQmain":0.9,"SDS":0.9,"DJX":0.9,"UDOW":0.9,"SPXU":0.9,"ESmain":0.9,"UPRO":0.9,"QLD":0.9,"SQQQ":0.9,"OEF":0.9,"OEX":0.9,"DXD":0.9,".IXIC":0.9,"QID":0.9,"DDM":0.9,"DOG":0.9,".SPX":0.9,"SH":0.9,"SDOW":0.9}},"isVote":1,"tweetType":1,"viewCount":4106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313562295,"gmtCreate":1611739764717,"gmtModify":1704862515159,"author":{"id":"3569217644250851","authorId":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569217644250851","idStr":"3569217644250851"},"themes":[],"title":"","htmlText":".....","listText":".....","text":".....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313562295","repostId":"1179238944","repostType":4,"isVote":1,"tweetType":1,"viewCount":3100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}